Truvian operates as a healthcare company. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. It provides lab-accurate results in less time for a comprehensive suite of health tests. It was formerly known as Salveo Dx. It was founded in 2015 and is based in San Diego, California.
ESPs containing Truvian
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The point-of-care blood tests market aims to provide rapid access to lab results for physicians, improving patient outcomes, office efficiency, patient satisfaction, and lowering overall healthcare costs. The market addresses the challenge of delays in working with third-party labs. It also satisfies an urgent need for accurate, rapid, and deployable diagnostic testing that is accessible and affor…
Truvian's Products & Differentiators
We are not revealing the name yet and will call it our core technology for now
Truvian’s compact instrument will deliver a convenient and affordable alternative to offsite laboratories, providing lab-accurate rapid insights to inform healthcare decisions. The groundbreaking diagnostic platform combines clinical chemistry, immunoassay, and hematology simultaneously within one instrument.
Expert Collections containing Truvian
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Truvian is included in 1 Expert Collection, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Truvian has filed 14 patents.
Transfusion medicine, Blood, Red blood cell disorders, Blood tests, Hematology
Transfusion medicine, Blood, Red blood cell disorders, Blood tests, Hematology
Latest Truvian News
Oct 4, 2023
Data demonstrates Truvian’s technology is reproducible and meets linearity and sensitivity specifications for a wide range of assays. Michael Barbella, Managing Editor10.04.23 Truvian Health is sharing results from a recent multi-site clinical study that demonstrates the ability of its benchtop blood testing platform to deliver central laboratory quality results simultaneously across a large assay panel. Data presented include results of a multi-site method comparison study of 237 donor samples run on both Truvian’s platform and central laboratory analyzers. The sample population consisted of apparently healthy donors (49%), donors with chronic disease (43%) and contrived samples (8%). Truvian’s platform showed excellent agreement to central laboratory analyzers in almost all assays in its panel. “For the first time in our industry, we have demonstrated that central lab quality results across three testing technologies are achievable on a benchtop platform from a single tube of blood,” Truvian Health Co-Founder/Chief Operating Officer Dena Marrinucci, Ph.D., said. “We aim to bring the central lab closer to patients. In doing so, we believe Truvian’s solution will empower greater interactions between patients and healthcare providers.” Truvian also released results from a reproducibility study to evaluate performance of multiple machines over multiple days. That study assessed variance of its technology with multiple replicates of low, normal and high-level controls run on three different machines over a five-day period. Truvian’s platform achieved acceptance criteria for 99% of 25 assays evaluated, with just a single outlier observed in 4,500 results from 180 runs. Additional data demonstrated linearity and sensitivity achieved across clinically relevant measuring ranges. Among the assays highlighted, most notably, Truvian’s technology can detect low abundance targets like thyroid stimulating hormone (TSH) with data that supports a lower limit of quantitation on par with third generation TSH assays. “The data we continue to generate in the field, and within Truvian has demonstrated the art of the possible in decentralized blood diagnostics," Truvian Health CEO Jay Srinivasan stated. "We believe our platform can have a significant impact on the healthcare system by bringing accurate, convenient and transparent blood testing to the point-of-action where patients and healthcare providers engage. With reliable results available in minutes, we hope to spur interactions that identify chronic disease before it begins and empower individuals toward longer, healthier living. We are excited about the significant progress we’ve made and look forward to finishing the development of our product based on these results and additional upcoming studies.” Truvian’s Platform leverages three commonly used testing technologies—immunoassay, clinical chemistry, and hematology to simultaneously perform routine blood testing in minutes from a small sample of blood. With an initial testing panel of more than 30 assays, the Truvian Platform can run the most commonly ordered tests that account for greater than 90% of blood test orders. This fully automated solution has been designed to use pre-packaged single use test kits, with minimal maintenance needed to ensure the technology can be used consistently and reliably anywhere. Truvian is a diagnostic company bringing lab-accurate results to the point of action. With a focus on making routine blood testing accessible, convenient, and transparent, Truvian is accelerating the transition to a sustainable healthcare ecosystem through its benchtop solution that delivers timely, actionable results to help stop disease before it starts.
Truvian Frequently Asked Questions (FAQ)
When was Truvian founded?
Truvian was founded in 2015.
Where is Truvian's headquarters?
Truvian's headquarters is located at 10300 Campus Point Drive, Suite 190, San Diego.
What is Truvian's latest funding round?
Truvian's latest funding round is Series C.
How much did Truvian raise?
Truvian raised a total of $150.1M.
Who are the investors of Truvian?
Investors of Truvian include GreatPoint Ventures, DNS Capital, Glen Tullman, TYH Ventures, General Catalyst and 8 more.
Who are Truvian's competitors?
Competitors of Truvian include Sight Diagnostics and 2 more.
What products does Truvian offer?
Truvian's products include We are not revealing the name yet and will call it our core technology for now and 1 more.
Compare Truvian to Competitors
PixCell Medical Technologies is a company focused on the development of diagnostic tools in the healthcare industry. The company's main product is a portable Point of Care (POC) blood diagnostic solution that simplifies blood testing for physicians and patients, enabling rapid blood test diagnostics and information for critical decisions. The primary sectors that PixCell Medical Technologies serves are the healthcare and medical treatment industries. It was founded in 2009 and is based in Yokneam, Israel. PixCell Medical Technologies operates as a subsidiary of Soulbrain.
OncoHost operates as a technology company to focuses on precision oncology. The company's main service is its proprietary platform, PROphet®, which uses artificial intelligence and plasma proteomic profiling to predict the clinical benefit of anti-PD-1/PD-L1 treatment for cancer patients, providing actionable clinical insights and optimal therapy choices. It primarily serves the healthcare industry, specifically the oncology sector. The company was founded in 2017 and is based in Binyamina, Israel.
Founded in 2004, PinPointe USA, Inc. is a privately held, emerging medical technology with headquarters in Chico, California.
EfA Technologies is a company focused on healthcare technology, specifically in the domain of diagnostic tools. The company offers a portable device that can perform lab-quality blood tests, including a complete blood count, in a matter of minutes without the need for expert preparation or laboratory conditions. The device is primarily aimed at improving access to essential diagnostic tests for people who live far from clinics or cannot afford traditional testing methods. It was founded in 2016 and is based in Yokneam, Israel.
Oxford Immune Algorithmics is a deep-tech start-up focused on the healthcare industry, with a particular emphasis on precision health and predictive medicine. The company offers a suite of solutions, known as Algocyte, which uses Artificial General Intelligence to monitor health remotely through intelligent testing, data collection, and analysis of various data streams, including clinical and lifestyle data. These solutions are designed to create a dynamic health picture for each individual, enabling early detection of health deviations and providing support for clinical decision-making. It was founded in 2018 and is based in Reading, England.
Beckman Coulter is a company focused on advanced diagnostics in the healthcare sector. The company offers a range of diagnostic solutions used in complex clinical testing, including chemistry, immunoassay, hematology, urinalysis, microbiology, blood banking, and protein chemistry. These solutions primarily cater to hospitals, reference laboratories, and physician office settings. It was founded in 1935 and is based in Brea, California.